Spectrum Pharmaceuticals, Inc. is engaged in the business of acquiring, developing and commercializing generic drug products that have a primary focus on the treatment of cancer and related disorders. The Company has two strategies: the Oncology Strategy and the Generic Drug Strategy. The Oncology Strategy focuses on the acquisition, or in-licensing, and continued development of clinical-stage drugs for the treatment and supportive care of cancer patients. Spectrum has three drug candidates in clinical development: satraplatin, EOquin and elsamitrucin. The Company's Generic Drug Strategy is to identify and acquire distribution rights for selected generic drugs, both, directly and through alliances with third-party companies; apply the Company's expertise and experience to further develop and pursue regulatory approval for those drugs, either directly or through third-party alliances, and market and distribute those generic drugs into retail and institutional channels.